Key Points
- CEO Amit Kumar purchased 5,000 Anixa Biosciences shares at an average price of $3.17, investing $15,850 and increasing his ownership by 0.74% to 685,000 shares.
- The CEO has made several additional purchases since September, acquiring a combined 23,000 shares in recent insider transactions.
- ANIX recently traded at $2.99 with a market capitalization of about $104 million. Analyst sentiment is mixed, resulting in a consensus “Hold” rating and an average price target of $8.00.
Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar bought 5,000 shares of the stock in a transaction that occurred on Friday, October 30th. The stock was acquired at an average cost of $3.17 per share, for a total transaction of $15,850.00. Following the purchase, the chief executive officer owned 685,000 shares of the company's stock, valued at $2,171,450. This trade represents a 0.74% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Amit Kumar also recently made the following trade(s):
- On Thursday, October 22nd, Amit Kumar purchased 8,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $2.72 per share, with a total value of $21,760.00.
- On Thursday, September 24th, Amit Kumar purchased 7,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $2.78 per share, with a total value of $19,460.00.
- On Thursday, September 10th, Amit Kumar acquired 3,000 shares of Anixa Biosciences stock. The shares were bought at an average cost of $2.75 per share, for a total transaction of $8,250.00.
- On Thursday, September 10th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were bought at an average cost of $2.76 per share, for a total transaction of $13,800.00.
Anixa Biosciences Trading Down 4.2%
ANIX stock opened at $2.99 on Tuesday. Anixa Biosciences Inc has a 1-year low of $2.32 and a 1-year high of $5.46. The firm has a market cap of $103.94 million, a P/E ratio of -9.34 and a beta of 0.47. The business's 50 day moving average is $2.96 and its 200-day moving average is $2.97.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.08). Sell-side analysts forecast that Anixa Biosciences Inc will post -0.31 EPS for the current year.
Institutional Investors Weigh In On Anixa Biosciences
Several institutional investors have recently modified their holdings of ANIX. Sanctuary Advisors LLC acquired a new position in Anixa Biosciences in the second quarter valued at approximately $29,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Anixa Biosciences during the 2nd quarter worth $29,000. Integrated Wealth Concepts LLC acquired a new stake in Anixa Biosciences during the 2nd quarter worth $30,000. Simplicity Wealth LLC bought a new stake in shares of Anixa Biosciences during the 2nd quarter valued at $34,000. Finally, NewEdge Wealth LLC bought a new stake in shares of Anixa Biosciences during the 2nd quarter valued at $35,000. Institutional investors and hedge funds own 29.13% of the company's stock.
Wall Street Analysts Forecast Growth
ANIX has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of Anixa Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday. HC Wainwright dropped their price objective on shares of Anixa Biosciences from $7.00 to $6.00 and set a "buy" rating for the company in a report on Tuesday, September 22nd. Citigroup reissued a "buy" rating on shares of Anixa Biosciences in a report on Tuesday, October 6th. Weiss Ratings raised Anixa Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, September 17th. Finally, Zacks Research cut Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 19th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Anixa Biosciences has a consensus rating of "Hold" and an average target price of $8.00.
Get Our Latest Stock Analysis on ANIX
Anixa Biosciences Company Profile
(
Get Free Report)
Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. The company's programs are designed to use the immune system to identify and attack disease-associated targets.
Anixa's oncology pipeline has included a chimeric antigen receptor T-cell (CAR-T) therapy targeting the follicle-stimulating hormone receptor, which is being investigated as a potential treatment for ovarian cancer and other cancers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
